Prosavin®, a dopamine gene therapy for advanced Parkinson’s disease: 5 years phase I/II clinical update
Date: October 17, 2018
Time: 13:10-15:10 CEST
Location: Garden Floor, Poster session 1
Poster Number: P201
AXO-Lenti-PD for Parkinson’s disease: endogenous dopamine production by intraputamenal three-gene transfer
Presented by: Fraser Wright, Chief Technology Officer of Axovant
During the lunch workshop on the use of lentiviral vectors for in vivo gene therapy
Date: October 18, 2018
Time: 13:15-14:15 CEST
Location: Garden Floor, Conference room 2/3
Fraser (formerly Co Founder and Chief Technology Officer
Spark Therapeutics, Inc.)
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM